Adjuvant therapy for colon and rectal cancer

Racial/Ethnic and Socioeconomic Differences in Colorectal and Breast Cancer Treatment Quality

“…We used the NIH Consensus Guidelines, 2–4 NCCN practice guidelines (http://www.nccn.org/professionals/physician_gls/f_guidelines.asp), and prior studies on cancer quality of care 5,18,30,34,35 to define reasonable time periods for the use of each guideline-recommended treatment. Breast cancer measures included: (1) receipt of BCS for stage I and II; (2) use of radiation within 12 months of BCS; and (3) use of chemo therapy for stage II hormone receptor-negative tumors within 12 months of surgery.…”

“…1 Highly effective treatments are available, 2–4 yet evidence shows that these treatments are significantly underused in vulnerable populations, including minority and less affluent groups. 5−18 Minority women with breast cancer are less likely to receive radiation and chemotherapy than white women 5–9,18 ; similarly, minority patients are less likely to receive chemotherapy for colon cancer, and radiation therapy for rectal cancer, than white patients.…”

Racial/Ethnic and Socioeconomic Differences in Colorectal and Breast Cancer Treatment Quality

“…We used the NIH Consensus Guidelines, 2–4 NCCN practice guidelines (http://www.nccn.org/professionals/physician_gls/f_guidelines.asp), and prior studies on cancer quality of care 5,18,30,34,35 to define reasonable time periods for the use of each guideline-recommended treatment. Breast cancer measures included: (1) receipt of BCS for stage I and II; (2) use of radiation within 12 months of BCS; and (3) use of chemo therapy for stage II hormone receptor-negative tumors within 12 months of surgery.…”

“…1 Highly effective treatments are available, 2–4 yet evidence shows that these treatments are significantly underused in vulnerable populations, including minority and less affluent groups. 5−18 Minority women with breast cancer are less likely to receive radiation and chemotherapy than white women 5–9,18 ; similarly, minority patients are less likely to receive chemotherapy for colon cancer, and radiation therapy for rectal cancer, than white patients.…”

Ist die adjuvante Chemotherapie von Kolonkarzinomen (Dukes C; TxN +) heute als Standard anzusehen?

“…Eine Konsensuskonferenz des National Cancer Institutes (USA) hat sich im April 1990 ebenfalls intensiv mit der adjuvanten Therapie beim kolorektalen Karzinom auseinandergesetzt, insbesondere auf dem Hintergrund der bestehenden Unsicherheiten [7]. Auch diese Expertengruppe kam zu der SchluBfolgerung, dab es derzeit keine optimale adjuvante Therapie fiir Patienten mit Kolonkarzinom im Stadium Dukes B und C gibt, und dab weitere klinische Studien dringend erforderlich sind, um aktivere und erfolgversprechendere Strategien zu entwikkeln.…”

Racial/Ethnic and Socioeconomic Differences in Colorectal and Breast Cancer Treatment Quality

“…We used the NIH Consensus Guidelines, 2–4 NCCN practice guidelines (http://www.nccn.org/professionals/physician_gls/f_guidelines.asp), and prior studies on cancer quality of care 5,18,30,34,35 to define reasonable time periods for the use of each guideline-recommended treatment. Breast cancer measures included: (1) receipt of BCS for stage I and II; (2) use of radiation within 12 months of BCS; and (3) use of chemo therapy for stage II hormone receptor-negative tumors within 12 months of surgery.…”

“…1 Highly effective treatments are available, 2–4 yet evidence shows that these treatments are significantly underused in vulnerable populations, including minority and less affluent groups. 5−18 Minority women with breast cancer are less likely to receive radiation and chemotherapy than white women 5–9,18 ; similarly, minority patients are less likely to receive chemotherapy for colon cancer, and radiation therapy for rectal cancer, than white patients.…”

Ist die adjuvante Chemotherapie von Kolonkarzinomen (Dukes C; TxN +) heute als Standard anzusehen?

“…Eine Konsensuskonferenz des National Cancer Institutes (USA) hat sich im April 1990 ebenfalls intensiv mit der adjuvanten Therapie beim kolorektalen Karzinom auseinandergesetzt, insbesondere auf dem Hintergrund der bestehenden Unsicherheiten [7]. Auch diese Expertengruppe kam zu der SchluBfolgerung, dab es derzeit keine optimale adjuvante Therapie fiir Patienten mit Kolonkarzinom im Stadium Dukes B und C gibt, und dab weitere klinische Studien dringend erforderlich sind, um aktivere und erfolgversprechendere Strategien zu entwikkeln.…”

Racial/Ethnic and Socioeconomic Differences in Colorectal and Breast Cancer Treatment Quality

“…We used the NIH Consensus Guidelines, 2–4 NCCN practice guidelines (http://www.nccn.org/professionals/physician_gls/f_guidelines.asp), and prior studies on cancer quality of care 5,18,30,34,35 to define reasonable time periods for the use of each guideline-recommended treatment. Breast cancer measures included: (1) receipt of BCS for stage I and II; (2) use of radiation within 12 months of BCS; and (3) use of chemo therapy for stage II hormone receptor-negative tumors within 12 months of surgery.…”

“…1 Highly effective treatments are available, 2–4 yet evidence shows that these treatments are significantly underused in vulnerable populations, including minority and less affluent groups. 5−18 Minority women with breast cancer are less likely to receive radiation and chemotherapy than white women 5–9,18 ; similarly, minority patients are less likely to receive chemotherapy for colon cancer, and radiation therapy for rectal cancer, than white patients.…”

Ist die adjuvante Chemotherapie von Kolonkarzinomen (Dukes C; TxN +) heute als Standard anzusehen?

“…Eine Konsensuskonferenz des National Cancer Institutes (USA) hat sich im April 1990 ebenfalls intensiv mit der adjuvanten Therapie beim kolorektalen Karzinom auseinandergesetzt, insbesondere auf dem Hintergrund der bestehenden Unsicherheiten [7]. Auch diese Expertengruppe kam zu der SchluBfolgerung, dab es derzeit keine optimale adjuvante Therapie fiir Patienten mit Kolonkarzinom im Stadium Dukes B und C gibt, und dab weitere klinische Studien dringend erforderlich sind, um aktivere und erfolgversprechendere Strategien zu entwikkeln.…”